[Frontiers in Bioscience 15, 57-64, January 1, 2010]

Functional genomics in identification of drug targets in Dupuytren's contracture

Mirela Sedic1, Davor Jurisic2,Zdenko Stanec3, Karlo Hock1, Kresimir Pavelic1,4, Sandra Kraljevic Pavelic1,4

1Rudjer Boskovic Institute, Division of Molecular Medicine, Laboratory for systems biology, Bijenicka c. 54, 10000 Zagreb, Croatia, 2University Hospital Center Rijeka, Clinic for Surgery, Department for Plastic and Reconstructive Surgery, Kresimirova 42a, 51000 Rijeka, Croatia, 3University Hospital Dubrava, Clinic for Plastic, Reconstructive and Aesthetic Surgery, Avenija Gojka Suska 6, 10 000 Zagreb, Croatia, 4University of Rijeka, Department of, Trsat, 51000 Rijeka, Croatia, Croatia


Figure 1. Hypothetical prediction of common regulatory mechanisms that control expression of the genes involved in Dupuytren's contracture pathogenesis. Differentially expressed proteins between affected and unaffected patient-matched tissue samples (41) were used to create the sets of genes that were entered into the CREME database. Two possible clusters of genes that are co-regulated at the transcriptional level were identified: one including the transcription factors SP1, CAC-binding protein, and the sterol regulatory element binding transcription factor 1 (SREBF1), and the other including SP1, CAC-binding protein, and heat shock transcription factor 1 (HSF1). TSS - transcription start site.

Figure 2. Functional genomics approach into studying the molecular processes underlying Dupuytren's contracture pathogenesis. The ability to combine diverse high-throughput methods from functional genomics and proteomics with bioinformatics will profoundly change the study of molecular mechanisms of diverse diseases and enable novel insights into disease pathogenesis.